Demographic and clinical data for controls as well as patients with lymphoid and myeloid neoplasms
| Variable . | Healthy controls, n = 91∗ . | Lymphoid neoplasms, n = 42∗ . | Myeloid neoplasms, n = 88∗ . | P value† . |
|---|---|---|---|---|
| Age (y) | 52 (38; 62) | 66 (48; 74) | 62 (52; 67) | < .001 |
| Sex | .033 | |||
| Female | 54 (59%) | 17 (40%) | 37 (42%) | |
| Male | 37 (41%) | 25 (60%) | 51 (58%) | |
| WBC | 6.10 (5.30; 7.75) | 5.40 (4.10; 6.77) | 6.00 (4.27; 8.38) | .2 |
| SARS-CoV-2 vaccination scheme | .07 | |||
| Vector based | 13 (14%) | 4 (9.5%) | 11 (12%) | |
| 2× mRNA-based | 62 (68%) | 37 (88%) | 69 (78%) | |
| Only one‡ | 16 (18%) | 1 (2.4%) | 8 (9.1%) | |
| Prior SARS-CoV-2 infection | .7 | |||
| Yes | 3 (3.3%) | 1 (2.4%) | 5 (5.7%) | |
| No | 88 (97%) | 41 (98%) | 83 (94%) | |
| Current cancer treatment | .04 (lymphoid vs myeloid) | |||
| Yes | 0 (0%) | 21 (50%) | 60 (68%) | |
| No | 91 (100%) | 21 (50%) | 28 (32%) |
| Variable . | Healthy controls, n = 91∗ . | Lymphoid neoplasms, n = 42∗ . | Myeloid neoplasms, n = 88∗ . | P value† . |
|---|---|---|---|---|
| Age (y) | 52 (38; 62) | 66 (48; 74) | 62 (52; 67) | < .001 |
| Sex | .033 | |||
| Female | 54 (59%) | 17 (40%) | 37 (42%) | |
| Male | 37 (41%) | 25 (60%) | 51 (58%) | |
| WBC | 6.10 (5.30; 7.75) | 5.40 (4.10; 6.77) | 6.00 (4.27; 8.38) | .2 |
| SARS-CoV-2 vaccination scheme | .07 | |||
| Vector based | 13 (14%) | 4 (9.5%) | 11 (12%) | |
| 2× mRNA-based | 62 (68%) | 37 (88%) | 69 (78%) | |
| Only one‡ | 16 (18%) | 1 (2.4%) | 8 (9.1%) | |
| Prior SARS-CoV-2 infection | .7 | |||
| Yes | 3 (3.3%) | 1 (2.4%) | 5 (5.7%) | |
| No | 88 (97%) | 41 (98%) | 83 (94%) | |
| Current cancer treatment | .04 (lymphoid vs myeloid) | |||
| Yes | 0 (0%) | 21 (50%) | 60 (68%) | |
| No | 91 (100%) | 21 (50%) | 28 (32%) |